Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study
Fibrinogen does not relate to cardiovascular or muscle manifestations in COPD: cross-sectional data from the ERICA study
复制标题
DOI：
10.1136/thoraxjnl-2018-211556
复制
发表时间：
2018-12-01
期刊：
影响因子：
10
通讯作者：
Polkey, Michael I.
中科院分区：
文献类型：
--
作者：
Mohan, Divya;Forman, Julia R.;Polkey, Michael I.
心血管和骨骼肌表现构成COPD的重要合并症，全身炎症被认为是常见的机制联系。纤维蛋白原在COPD中具有预后作用。我们的目的是确定主动脉僵硬和股四头肌无力是否与COPD有关，以及它们是否与全身炎症介质纤维蛋白原有关。在729例稳定的慢性阻塞性肺疾病全球倡议（GOLD）II-IV期COPD患者中测量主动脉脉搏波速度（aPWV）、股四头肌最大自主收缩力（QMVC）和纤维蛋白原。心血管和肌肉表现独立存在（P=0.22，（2））。纤维蛋白原与aPWV或QMVC无关（分别为P=0.628和P=0.621），使得通过血浆纤维蛋白原测量的炎症不太可能是常见的病因学因素。
Cardiovascular and skeletal muscle manifestations constitute important comorbidities in COPD, with systemic inflammation proposed as a common mechanistic link. Fibrinogen has prognostic role in COPD. We aimed to determine whether aortic stiffness and quadriceps weakness are linked in COPD, and whether they are associated with the systemic inflammatory mediatorfibrinogen. Aortic pulse wave velocity (aPWV), quadriceps maximal volitional contraction (QMVC) force and fibrinogen were measured in 729 patients with stable, Global Initiative for Chronic Obstructive Lung Disease (GOLD) stages II-IV COPD. The cardiovascular and muscular manifestations exist independently (P=0.22, (2)). Fibrinogen was not associated with aPWV or QMVC (P=0.628 and P=0.621, respectively), making inflammation, as measured by plasma fibrinogen, an unlikely common aetiological factor.